Navigation Links
MedImmune Announces Positive Clinical Results at PAS Annual Meeting,From Large Prospective Trial in Prevention of Serious RSV Disease

dard of care."

The Phase 3 study was designed to compare the safety and efficacy of motavizumab with that of Synagis, which was first launched by MedImmune in 1998, in reducing serious RSV disease in high-risk infants in the inpatient and outpatient settings. As defined in the study, infants who are at high risk for RSV include those who were born at 35 weeks gestation or less as well as those who have chronic lung disease (CLD) due to being born prematurely. The primary endpoint was to assess the incidence of RSV hospitalizations with motavizumab compared to Synagis. Motavizumab met the primary endpoint, demonstrating non-inferiority to Synagis with 26 percent fewer RSV hospitalizations in motavizumab-treated infants. The overall RSV attack rate was low in both treatment groups: 1.4 percent for infants who received motavizumab, compared with 1.9 percent for those who received Synagis [RR: 0.740, 95 percent CI: (0.503, 1.083)]. The p-value for non-inferiority was p<0.01, demonstrating a significant finding.

Analysis of the data also showed that motavizumab reduced the incidence of RSV-specific medically attended outpatient LRIs (the study's RSV-related secondary endpoint) by approximately 50 percent compared with Synagis. The overall RSV-specific medically attended LRI rate was 2.0 percent for infants who received motavizumab compared with 3.9 percent for those who received Synagis (p<0.01). There were no significant differences in other non-RSV- specific endpoints.

"I am very pleased with the study results for motavizumab," said Xavier Carbonell, M.D., Ph.D., lead study author, chairman of neonatology, Barcelona Hospital Clinic, and vice president, Spanish Neonatal Society. "As a practicing neonatologist, I look forward to the potential to use this next- generation antibody to help reduce RSV-related hospitalizations and LRIs in the outpatient setting."

Data from this trial demonstrate that both study drugs were well tolerated. The incid
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Infinity and MedImmune Present Updated Phase I Results of IPI-504 in GIST at ASCO Annual Meeting
2. Infinity and MedImmune Announce Updated Data On Ipi-504 to be Presented At ASCO
3. MedImmune Highlights Advances in Inflammatory Disease Pipeline With Series of Data Presentations
4. Pediatric Academic Societies Annual Meeting to Feature Data Presentations Related to MedImmune Clinical Programs in Influenza, RSV and hMPV
5. Micromet Achieves Milestone in BiTE Research Collaboration with MedImmune
6. MedImmune Publishes New Data in Nature Immunology Demonstrating The Role HMGB1 May Play in Systemic Autoimmune Diseases
7. MedImmune and Micromet Publish Data on Novel Anti-Cancer BiTE Molecule
8. Micromet and MedImmune Present Data From Preclinical Study of New BiTE Molecule Targeting CEA
9. Infinity and MedImmune to Present Preclinical Data From Study of Oral Formulation of IPI-504 At AACR
10. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
11. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
Post Your Comments:
(Date:9/23/2014)... Sept. 23, 2014 Research and ... "Physician Office Laboratory Markets, 3rd Edition" ... report, Physician Office Laboratory Markets is Kalorama,s complete ... industry. Physician office laboratories are diverse in their ... reimbursable, in-office pregnancy and glucose tests. Some specialty ...
(Date:9/23/2014)... , September 23, 2014 ... has announced the addition of the  "Large ... to their offering.  ,     ... drug delivery market holds significant potential for ... vials and painful needles to the modern-day ...
(Date:9/23/2014)... 2014  SiteOne Therapeutics Inc. today announced the completion ... Sears Capital Management and Biobrit LLC, with additional investors ... $1.5 million financing positions SiteOne to advance its oral ... further develop its technology platform for long-acting local analgesics, ... conjunction with the financing, Lowell Sears (Sears ...
Breaking Medicine Technology:Physician Office Laboratory Markets, 3rd Edition 2Physician Office Laboratory Markets, 3rd Edition 3Large Volume Wearable Injectors - 2nd Edition 2Large Volume Wearable Injectors - 2nd Edition 3Large Volume Wearable Injectors - 2nd Edition 4Large Volume Wearable Injectors - 2nd Edition 5SiteOne Therapeutics Completes $1.5M Initial Round of Equity Financing, Secures $1.4M NIH Grant 2SiteOne Therapeutics Completes $1.5M Initial Round of Equity Financing, Secures $1.4M NIH Grant 3
... New study questions ability of human-animal hybrids to generate ... Cell Technology, Inc. (OTC Pink Sheets: ACTC) and its ... the capacity to extensively reprogram adult human cells. The ... journal Cloning and Stem Cells (Editor-in-Chief: Sir ...
... Inc., the leader in the,development of devices for ... start of enrollment in the REALISM (Real World ... continued access,registry. The MitraClip(R) system is currently being ... option for patients suffering from the,effects of mitral ...
Cached Medicine Technology:Cloned Human Embryos Successfully Reprogrammed Using Human - But Not Animal - Eggs 2Cloned Human Embryos Successfully Reprogrammed Using Human - But Not Animal - Eggs 3Cloned Human Embryos Successfully Reprogrammed Using Human - But Not Animal - Eggs 4Cloned Human Embryos Successfully Reprogrammed Using Human - But Not Animal - Eggs 5First U.S. Patients Enrolled in the REALISM Continued Access Study 2First U.S. Patients Enrolled in the REALISM Continued Access Study 3
(Date:9/23/2014)... Academia Sinica, the preeminent academic institution in the ... collaborative agreement to develop a unique educational and ... opportunities to translate innovative technologies and commercially relevant ... signed Sept.12 in Taipei by Harris Lewin, vice ... Chi-Huey Wong of Academia Sinica. The program will ...
(Date:9/23/2014)... San Diego, CA (PRWEB) September 23, 2014 ... website daily regarding all the latest information from the ... announced on September 5, that its Private Label Jalapeno ... glass and small stones. Publix Jalapeno Bagels ... in the bakery department. , Taking into consideration ...
(Date:9/23/2014)... Kathleen Doheny HealthDay Reporter ... babies born at very low birth weights, breast milk is ... potentially dangerous infection known as cytomegalovirus (CMV), a new study ... birth weight infants -- all of whom weighed 3.3 pounds ... a history of CMV infection, to see whether breast milk ...
(Date:9/23/2014)... (HealthDay News) -- Both drinking and getting drunk at ... abuse by high school students, a new study suggests. ... school students who drink, could help expand alcohol-prevention efforts ... to stop them from becoming binge drinkers, the researchers ... first alcohol use and progression to first heavy use ...
(Date:9/23/2014)... Washington, DC (PRWEB) September 23, 2014 ... affordable care? The National Quality Forum (NQF) ... sheet ( http://www.qualityforum.org/WorkArea/linkit.aspx?LinkIdentifier=id&ItemID=77687 ), and an infographic ( ... the rising cost of healthcare, how patients define ... for consumers to get the best possible healthcare ...
Breaking Medicine News(10 mins):Health News:Academia Sinica, UC Davis sign agreement on exchanges and tech transfer 2Health News:Publix Private Label Jalapeno Bagels Recalled: AttorneyOne Monitors and Keeps Consumers Informed 2Health News:Breast Milk a Risk for Spreading Common Virus to Preemies, Study Finds 2Health News:Breast Milk a Risk for Spreading Common Virus to Preemies, Study Finds 3Health News:Younger Age at First Drink, Higher Odds for Problem Drinking: Study 2Health News:Younger Age at First Drink, Higher Odds for Problem Drinking: Study 3Health News:Finding Affordable Care: Asking the Right Question is Key 2
... In response to the recent media attention on ... Williamsburg Place , one of the nation,s leading addiction treatment ... Omar S. Manejwala, M.D., Associate Medical Director for the Farley Center ... area and has appeared nationally recently on programs such as the ...
... WORCESTER, Mass., July 17 The Hanover Insurance Group (NYSE: ... announced the availability of a new product offering that can extend homeowners ... , , (Logo: ... The coverage is more important than ever as the population of people ...
... temperament, study finds , FRIDAY, July 17 (HealthDay News) -- ... may have nothing to do with your parenting skills because ... of brain activity may determine a child,s temperament, a new ... the DRD4 gene and activity in the frontal cortex of ...
... N.C., July 17 Rabies is a virus that occurs in mammals ... humans if it is not treated. Nearly 90 percent of cases occur ... occur in domestic animals like dogs or cats. Humans usually become infected ... , Early symptoms of rabies are fever, headache and ...
... , , , GLASGOW, ... the UK would most like to be the national emblem of England, ... comes from a new survey commissioned by AXA PPP healthcare,s Nutrition and ... the EU lifted its ban on the sale of ,misshapen, produce such ...
... The ... Partner at the law firm of Loeb & Loeb LLP, as Chair, and Sheldon Kwiat, President ... ... YAI/National Institute for People with Disabilities (YAI/NIPD) Board of Trustees has elected Eliot Green, a ...
Cached Medicine News:Health News:Omar S. Manejwala, MD Speaks Out Nationally on Diprivan/Propofol Abuse 2Health News:Omar S. Manejwala, MD Speaks Out Nationally on Diprivan/Propofol Abuse 3Health News:The Hanover Launches New Insurance Option to Protect Family Members in Assisted Living Facilities 2Health News:The Hanover Launches New Insurance Option to Protect Family Members in Assisted Living Facilities 3Health News:Easy Baby or Fussy -- It May Be Out of Mom's Control 2Health News:Rabies: How to Protect Yourself and Your Pets 2Health News:Potato Tops Poll To Be UK's National Veg 2Health News:YAI/NIPD Board of Trustees Elects Eliot Green Chair and Sheldon Kwiat Vice Chair 2Health News:YAI/NIPD Board of Trustees Elects Eliot Green Chair and Sheldon Kwiat Vice Chair 3Health News:YAI/NIPD Board of Trustees Elects Eliot Green Chair and Sheldon Kwiat Vice Chair 4
0.5mm "K" hook. Rounded knurled handle; shaft angled 11mm from tip; overall length 120mm, in Titanium....
Lightly Curved-Blunt Tips Rounded Blades; 1mm Eye in Blades; 27mm from mid screw to tip. Matte finish; Stainless Steel, overall length 120mm...
... Perfusion Catheter is indicated for ... portion of a coronary artery ... the purpose of improving myocardial ... are also designed to provide ...
... The eSpeed C300 uses its hallmark 50 and ... techniques. New MultiPhase scan protocols and proprietary ... C300s four beam targets and two x-ray detector ... arteries and analyze myocardial perfusion and wall motion. ...
Medicine Products: